The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents
- PMID: 17332455
- DOI: 10.1161/01.STR.0000260087.67462.80
The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents
Abstract
Clinical trials for acute stroke treatments have often used composite clinical rating scales as primary outcome measures of treatment efficacy. Recent preclinical and clinical studies highlight the opportunity to administer treatments in the subacute and chronic phase of stroke to promote neurological recovery. Because different neurological deficits recover to different extents at different rates after stroke, putative stroke recovery-promoting treatments may exert differential effects on various functional aspects of stroke recovery. For this reason, we propose that the use of modality-specific outcome measures may be best suited as primary end points in clinical trials of stroke recovery-promoting agents. The use of such end points may result in a more selective labeling of stroke recovery treatments.
Similar articles
-
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717
-
Optimising outcome assessment to improve quality and efficiency of stroke trials.Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):101-11. doi: 10.1586/14737167.2014.870479. Epub 2013 Dec 19. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24350886 Review.
-
Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures.Spinal Cord. 2007 Mar;45(3):206-21. doi: 10.1038/sj.sc.3102008. Epub 2006 Dec 19. Spinal Cord. 2007. PMID: 17179972 Review.
-
Need to clarify Thrombolysis In Myocardial Ischemia (TIMI) scale scoring method in the Penumbra Pivotal Stroke Trial.Stroke. 2010 Feb;41(2):e115-6. doi: 10.1161/STROKEAHA.109.566406. Epub 2009 Dec 24. Stroke. 2010. PMID: 20035075 No abstract available.
-
Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials.Stroke. 2007 Nov;38(11):3055-62. doi: 10.1161/STROKEAHA.107.488536. Epub 2007 Oct 4. Stroke. 2007. PMID: 17916765 Review.
Cited by
-
Transforming modeling in neurorehabilitation: clinical insights for personalized rehabilitation.J Neuroeng Rehabil. 2024 Feb 4;21(1):18. doi: 10.1186/s12984-024-01309-w. J Neuroeng Rehabil. 2024. PMID: 38311729 Free PMC article.
-
Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials.Stroke. 2014 Feb;45(2):634-9. doi: 10.1161/STROKEAHA.113.003379. Epub 2013 Dec 24. Stroke. 2014. PMID: 24368562 Free PMC article. Review. No abstract available.
-
Brain repair: cell therapy in stroke.Stem Cells Cloning. 2014 Feb 21;7:31-44. doi: 10.2147/SCCAA.S38003. eCollection 2014. Stem Cells Cloning. 2014. PMID: 24627643 Free PMC article. Review.
-
Genetic Variation and Neuroplasticity: Role in Rehabilitation After Stroke.J Neurol Phys Ther. 2017 Jul;41 Suppl 3(Suppl 3 IV STEP Spec Iss):S17-S23. doi: 10.1097/NPT.0000000000000180. J Neurol Phys Ther. 2017. PMID: 28628592 Free PMC article. Review.
-
Resting-state functional abnormalities in ischemic stroke: a meta-analysis of fMRI studies.Brain Imaging Behav. 2024 Dec;18(6):1569-1581. doi: 10.1007/s11682-024-00919-1. Epub 2024 Sep 9. Brain Imaging Behav. 2024. PMID: 39245741
